Synthesis and Bioactivities of Leflunomide analogs
碩士 === 國防醫學院 === 藥學研究所 === 93 === Abstract Leflunomide(LEM) has been approved as a newest disease-modifying antirheumatic drug by the FDA in 1998. Being a prodrug, LEM was rapidly converted in vivo to its active metabolite MNA. The active metabolite acts by inhibiting dihydroorotate dehydrogenase,...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2005
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/97959311808555901795 |